Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy

Background & Aims Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy. The phase 3 randomized, controlled studies, Eltrombopag to Initiate and Mai...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2014-02, Vol.146 (2), p.442-452.e1
Hauptverfasser:	Afdhal, Nezam H, Dusheiko, Geoffrey M, Giannini, Edoardo G, Chen, Pei–Jer, Han, Kwang–Hyub, Mohsin, Aftab, Rodriguez–Torres, Maribel, Rugina, Sorin, Bakulin, Igor, Lawitz, Eric, Shiffman, Mitchell L, Tayyab, Ghias–Un–Nabi, Poordad, Fred, Kamel, Yasser Mostafa, Brainsky, Andres, Geib, James, Vasey, Sandra Y, Patwardhan, Rita, Campbell, Fiona M, Theodore, Dickens
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antiviral Agents - therapeutic use Benzoates - therapeutic use Blood Clot Complication Drug Administration Schedule Female Follow-Up Studies Gastroenterology and Hepatology Hematologic Agents - therapeutic use Hepatitis C, Chronic - blood Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Humans Hydrazines - therapeutic use Induction Chemotherapy Intention to Treat Analysis Interferon-alpha - therapeutic use Liver Cirrhosis - blood Liver Cirrhosis - complications Liver Cirrhosis - virology Liver Disease Maintenance Chemotherapy Male Middle Aged Platelet Count Polyethylene Glycols - therapeutic use Portal Hypertension Pyrazoles - therapeutic use Recombinant Proteins - therapeutic use Ribavirin - therapeutic use Thrombocytopenia - blood Thrombocytopenia - drug therapy Thrombocytopenia - virology Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background & Aims Thrombocytopenia is common among patients with hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-alfa (PEG) and ribavirin (RBV) therapy. The phase 3 randomized, controlled studies, Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C-Related Liver Disease (ENABLE)-1 and ENABLE-2, investigated the ability of eltrombopag to increase the number of platelets in patients, thereby allowing them to receive initiation or maintenance therapy with PEG and RBV. Methods Patients with HCV infection and thrombocytopenia (platelet count
ISSN:	0016-5085 1528-0012
DOI:	10.1053/j.gastro.2013.10.012